Jun 10, 2026
17 MIN READ

The Journey of GLP-1 Medications: How Long Have They Been on the Market?

GLP-1 receptor agonists emerged from diabetes research in the 1990s and have transformed into the fastest-growing weight loss medications in history. PlexusDx provides compounded GLP-1 therapy starting at $149/month.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 10, 2026
17 MIN READ

the journey of glp-1 medications: how long have they been on the market? — PlexusDx GLP-1 education

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Glucagon-like peptide-1 (GLP-1) medications have moved from niche diabetes treatment to mainstream weight loss therapy in less than a decade, but their clinical foundation spans over thirty years. The story of how these compounds reached patients reflects decades of pharmaceutical innovation, regulatory approval, and real-world clinical outcomes that now benefit millions seeking sustainable weight management.

When Did GLP-1 Medications First Enter Clinical Use?

Scientists first identified and isolated glucagon-like peptide-1 in 1987, beginning a multi-decade journey toward therapeutic application. This natural hormone, produced in the intestinal tract, regulates blood glucose and appetite—properties that would eventually unlock modern weight loss medicine. Early research demonstrated that activating GLP-1 receptors could improve insulin secretion in patients with type 2 diabetes, establishing the biological mechanism that later medications would target.

The first GLP-1 receptor agonist, exenatide, received FDA approval in 2005 as an injectable diabetes medication. This marked the transition from laboratory discovery to patient treatment, though the drug required twice-daily injections and reached only a limited market. Exenatide's success proved the therapeutic viability of GLP-1 pathway activation, creating momentum for developers to create longer-acting formulations that would eventually expand to weight loss indications.

The Evolution From Diabetes Therapy to Weight Loss Treatment

Semaglutide emerged as a once-weekly injectable GLP-1 agonist in 2017, initially approved by the FDA for type 2 diabetes management under the brand name Ozempic. Clinical trials showed that semaglutide produced consistent blood glucose control with an unexpected additional benefit: patients experienced significant weight loss as a secondary outcome. This observation shifted focus within the medical community and pharmaceutical industry toward semaglutide's potential in metabolic weight management beyond diabetes.

In November 2021, the FDA approved semaglutide specifically for chronic weight management at higher doses under the brand name Wegovy, formally recognizing weight loss as a primary therapeutic indication. This approval represented a watershed moment—the first major pharmaceutical company officially positioning a GLP-1 medication for patients without diabetes seeking weight reduction. Within months, demand exceeded supply, and compounding pharmacies began providing access to those facing shortages or seeking more affordable alternatives through licensed 503A compounding channels.

Tirzepatide's Recent Market Entry and Dual-Peptide Innovation

Tirzepatide introduced a new mechanism in 2022 by simultaneously activating both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors—a dual-peptide approach not previously available in weight loss therapy. The FDA approved tirzepatide for type 2 diabetes in November 2022 under the brand name Mounjaro, followed by weight loss approval in November 2023 as Zepbound. Clinical trials demonstrated that tirzepatide produced greater weight loss than semaglutide monotherapy, typically 20–22% body weight reduction compared to 15–17% with semaglutide alone.

The rapid approval timeline for tirzepatide's weight loss indication reflected growing regulatory recognition of the GLP-1 and GIP pathways' significance in metabolic health. PlexusDx now offers tirzepatide starting at $249/month through licensed 503A compounding pharmacies, providing patients access to this newer dual-peptide option without insurance requirements. The emergence of tirzepatide alongside semaglutide has created a competitive landscape where patients can work with providers to select the compound best aligned with their individual metabolic profile and clinical goals.

How Long Have GLP-1 Medications Been Safe and Effective?

Safety data for GLP-1 receptor agonists now spans nearly two decades of clinical use, beginning with exenatide in 2005 and expanding through semaglutide trials that enrolled tens of thousands of participants. The most common adverse effects—nausea, vomiting, and gastrointestinal symptoms—typically appear during dose escalation and diminish as the body adapts. Serious adverse events remain rare, with pancreatitis and gallbladder complications reported at low frequencies comparable to or lower than placebo groups in major clinical trials.

Long-term efficacy studies demonstrate that GLP-1 medications sustain weight loss and metabolic improvements when patients maintain treatment. The STEP and SELECT trials, which enrolled over 20,000 total participants and followed outcomes for up to four years, showed durable weight reduction, improved cardiovascular markers, and reduced major adverse cardiac events. PlexusDx supports patients through ongoing monitoring and precision genetic testing via the Precision Peptide Genetic Test ($99 add-on), which identifies individual variations in peptide pathways—such as GLP1R rs6923761 and GIPR rs1800437—to optimize compound selection and dosing strategy for each patient.

Why the Market Has Grown So Rapidly Since 2021

The explosion in GLP-1 popularity since Wegovy's 2021 approval reflects a convergence of clinical evidence, unmet medical need, and supply dynamics that transformed the weight loss landscape. Approximately 40% of American adults struggle with obesity, yet previous pharmaceutical options offered modest results—averaging 5–10% weight loss versus 15–22% with GLP-1 therapy. Media attention, celebrity endorsements, and viral social sharing accelerated public awareness beyond traditional pharmaceutical channels, creating unprecedented demand that initially outpaced manufacturer supply.

Licensed 503A compounding pharmacies entered the market in 2023–2024 to address access gaps and cost barriers, enabling patients to obtain compounded semaglutide and tirzepatide without insurance or membership requirements—pricing that starts at $149/month for compounded semaglutide injection. PlexusDx serves all 50 states with HSA/FSA-eligible pricing, removing geographic and financial obstacles that previously limited access to these medications. This democratization of GLP-1 therapy has sustained demand growth and positioned compounded GLP-1 as a mainstream weight loss option rather than a specialty or exclusive treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How long have GLP-1 medications actually been available to patients?

The first GLP-1 receptor agonist, exenatide, entered the market in 2005 as a diabetes medication. Semaglutide launched in 2017 for diabetes, then received FDA approval for weight loss in November 2021. Tirzepatide's weight loss indication followed in November 2023. PlexusDx offers both compounded options starting at $149/month for semaglutide injection.

Is there clinical evidence that GLP-1 medications are safe long-term?

Yes. Safety data spans nearly two decades, with the most extensive modern trials (STEP and SELECT) following over 20,000 participants for up to four years. Serious adverse events remain rare, and weight loss benefits persist during continued treatment. PlexusDx monitors all patients and offers the Precision Peptide Genetic Test to personalize therapy based on individual peptide pathway variants.

Why are compounded GLP-1 medications available now if the branded versions already exist?

Licensed 503A compounding pharmacies began offering compounded semaglutide and tirzepatide in 2023–2024 to address supply shortages and cost barriers. PlexusDx provides these medications without insurance, membership fees, or membership requirements, with pricing that starts at $149/month for compounded semaglutide injection—significantly lower than many branded alternatives.

Are compounded GLP-1 medications as effective as branded versions?

Compounded medications from licensed 503A pharmacies contain the same active pharmaceutical ingredients as branded products and follow identical manufacturing standards. Efficacy depends on the compound itself (semaglutide or tirzepatide) and individualized dosing, not the compounding source. The PlexusDx Precision Peptide Genetic Test identifies genetic insights that help optimize which compound and dosing strategy works best for each patient.

How does the Precision Peptide Genetic Test help personalize my GLP-1 therapy?

The Precision Peptide Genetic Test ($99 add-on) analyzes 14 metabolic pathways and 150+ genetic insights, including key variants like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These findings help PlexusDx providers match you with semaglutide or tirzepatide and optimize your starting dose based on your individual peptide-pathway genetics, not just standard protocols.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves